Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| I7S-MC-HBEO | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at participants: thinking and memory (cognition), everyday activities and sleep, AD symptoms, physical activity, irritability or anxiety. The study is expected to last approximately 26 weeks and may include up to 14 visits.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mevidalen (high dose) | Experimental | Mevidalen high dose administered orally. |
|
| Mevidalen (low dose) | Experimental | Mevidalen low dose administered orally. |
|
| Placebo | Placebo Comparator | Placebo administered orally. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mevidalen | Drug | Administered orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) | iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance. | Baseline, Week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) | The ADAS-Cog13 consists of 13 items which assess the areas of cognitive function that are the most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation measures. The scale ranges from 0 to 85, with higher scores indicating greater disease severity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Banner Alzheimer's Institute | Phoenix | Arizona | 85006 | United States | ||
| Baptist Health Center for Clinical Research LLC |
Not provided
| Label | URL |
|---|---|
| A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Administered orally |
|
| Baseline, Week 24 |
| Change from Baseline in Verbal Fluency Test | The Verbal Fluency Test, also known as the FAS test, requires participants to say as many words as possible beginning with specific letters (F, A, and S) in 1 minute. The FAS score corresponds to the number of words generated by each participant under each letter category within 1 minute. A higher score indicates better performance. | Baseline, Week 24 |
| Change from Baseline in Category Fluency Test | The Category Fluency test is a measure of semantic memory and involves planning, organization, and cognitive flexibility. The participant is asked to generate as many words as possible in 1 minute that belong to the animal semantic category. Total score is the sum of correct words generated for the animal category, and higher values indicate better performance. | Baseline, Week 24 |
| Change from Baseline in Digit Symbol Coding Test( Wechsler Adult Intelligence Scale-IV)(WAIS-IV) | The Digit Symbol-Coding test from the WAIS-IV involves testing processing speed among subjects; The digit symbol coding requires a subject to match symbols to numbers according to a key. The number of correct symbols within the allowed time constitutes the score, and higher values indicate better performance. | Baseline, Week 24 |
| Change from Baseline in Mini Mental State Examination (MMSE) | The MMSE is a brief instrument used to assess global cognition. The instrument measures orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with lower score indicating greater level of impairment. | Baseline, Week 24 |
| Change from Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) | The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire that is to be answered by the participant's study partner. Study partner is asked to observe and rate the performance of activities of daily living attempted by participants. The range for the total ADCS-ADL score is 0 to 78, with lower scores indicating greater level of impairment. | Baseline, Week 24 |
| Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change score (ADCS-CGIC) | The ADCS-CGIC is a 7-point, categorical scale that provides a single global rating of change from baseline. A score of 1 indicates marked improvement; a score of 2, moderate improvement; a score of 3, minimal improvement; a score of 4, no change; a score of 5, minimal worsening; a score of 6, moderate worsening; and a score of 7, marked worsening. | Week 24 |
| Change from Baseline on Neuropsychiatric Inventory (NPI-12) | The NPI-12 is rating instrument to assess abnormal behaviors in dementia patients by informant-based interview that utilizes scripted questions to explore 12 different symptom domains: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity, night-time behavioral disturbances, and appetite and eating abnormalities. The frequency of behaviour is scored from 0 (Rarely) to 4 (very often) and the severity from 0 (mild) to 3 (severe). A total score for each symptom is calculated by multiplying the frequency rating by the severity rating. The total NPI-12 score is the sum of all symptom scores and ranges from 0 to 144, with higher scores indicating a greater degree of symptomatology. | Baseline, Week 24 |
| Change from Baseline on Epworth Sleepiness Scale (ESS) | ESS is an 8-item questionnaire that measures the chances of "dozing off" in different daytime situations over the past week. Scores range from 0 to 24, with scores greater than or equal to 10 indicating excessive daytime sleepiness. | Baseline, Week 24 |
| Change from Baseline on Quick Dementia Rating Scale (QDRS) | The QDRS is a 10-item rating scale that assesses aspects of cognition, behavior, and daily functioning on a 5-point scale where no problems = 0, slight problems = 0.5, mild problems = 1, moderate to severe problems = 2, and severe problems = 3. Total scores range from 0 to 30 and higher scores indicate increased cognitive impairment. | Baseline, Week 24 |
| Little Rock |
| Arkansas |
| 72205 |
| United States |
| Profound Research LLC At The Neurology Center of Southern California | Carlsbad | California | 92011 | United States |
| Neuropain Medical Center | Fresno | California | 93710 | United States |
| Catalina Research Institute | Montclair | California | 91763 | United States |
| California Neuroscience Research, LLC | Sherman Oaks | California | 91403 | United States |
| JEM Research Institute | Atlantis | Florida | 33462 | United States |
| Visionary Investigators Network | Aventura | Florida | 33180 | United States |
| Excel Medical Clinical Trials, LLC Boca Raton dba Flourish Research | Boca Raton | Florida | 33434 | United States |
| Vertex Clinical Research | Clermont | Florida | 34711 | United States |
| Neuropsychiatric Research Center of Southwest Florida | Fort Myers | Florida | 33912 | United States |
| Clinical Neuroscience Solutions, Inc. | Jacksonville | Florida | 32256 | United States |
| Merritt Island Medical Research, LLC dba Flourish Research | Merritt Island | Florida | 32952 | United States |
| Visionary Investigators Network | Miami | Florida | 33176 | United States |
| Suncoast Clinical Research - New Port Richey | New Port Richey | Florida | 34652 | United States |
| Renstar Medical Research | Ocala | Florida | 34470 | United States |
| Charter Research, LLC | Orlando | Florida | 32803 | United States |
| Progressive Medical Research | Port Orange | Florida | 32127 | United States |
| Intercoastal Medical Group | Sarasota | Florida | 34239 | United States |
| Brain Matters Research | Stuart | Florida | 34997 | United States |
| Charter Research - The Villages | The Villages | Florida | 32162 | United States |
| Premiere Research Institute at Palm Beach Neurology | West Palm Beach | Florida | 33407 | United States |
| Conquest Research | Winter Park | Florida | 32789 | United States |
| Accel Research Sites - NeuroStudies CRU | Decatur | Georgia | 30030 | United States |
| CenExel iResearch Atlanta | Decatur | Georgia | 30030 | United States |
| CenExel iResearch, LLC | Savannah | Georgia | 31405 | United States |
| Hawaii Pacific Neuroscience | Honolulu | Hawaii | 96817 | United States |
| Ascension Alexian Brothers | Elk Grove Village | Illinois | 60007 | United States |
| Josephson, Wallack, Munshower Neurology, P.C. | Indianapolis | Indiana | 46256 | United States |
| ActivMed Practices & Research, LLC | Methuen | Massachusetts | 01844 | United States |
| QUEST Research Institute | Farmington Hills | Michigan | 48334 | United States |
| CenExel Advanced Memory Research Institute of NJ | Toms River | New Jersey | 08755 | United States |
| AMC Research, LLC dba Flourish Research | Matthews | North Carolina | 28105 | United States |
| Eximia Clinical Research-NC, LLC | Raleigh | North Carolina | 27612 | United States |
| Keystone Clinical Studies, LLC Philadelphia dba Flourish Research | Plymouth Meeting | Pennsylvania | 19462 | United States |
| Clinical Neuroscience Solutions, Inc.Ta | Memphis | Tennessee | 38119 | United States |
| Senior Adults Specialty Research | Austin | Texas | 78757 | United States |
| Kerwin Medical Center | Dallas | Texas | 75231 | United States |
| Cedar Health Research, LLC | Euless | Texas | 76040 | United States |
| Clinical Trial Network LLC | Houston | Texas | 77074 | United States |
| El Faro Health and Therapeutics | Rio Grande City | Texas | 78582 | United States |
| Be Well Clinical Studies | Round Rock | Texas | 78681 | United States |
| Clinical Trials of Texas, LLC San Antonio dba Flourish Research | San Antonio | Texas | 78229 | United States |
| University of Washington Medical Center | Seattle | Washington | 98104 | United States |
| Akita City Hospital | Akita | 010-0933 | Japan |
| Memory Clinic Ochanomizu | Bunkyō City | 113-0034 | Japan |
| Inage Neurology and Memory Clinic | Chiba | 263-0043 | Japan |
| Ikuseikai Shinozuka Hospital | Fujioka-shi | 375-0017 | Japan |
| Mental Clinic Sakurazaka | Fukuoka | 810-0023 | Japan |
| Kuramitsu Hospital | Fukuoka | 819-0037 | Japan |
| Himeji Central Hospital Clinic | Himeji-shi | 672-8043 | Japan |
| Koseikai Cocoro Hospital Kusatsu | Hiroshima | 733-0864 | Japan |
| NHO Hizen Psychiatric Medical Center | Kanzaki-gun | 842-0192 | Japan |
| Rainbow & Sea Hospital | Karatsu-shi | 847-0031 | Japan |
| Kishikai Kishi Hospital | Kiryu-shi | 376-0011 | Japan |
| Southern TOHOKU Medical Clinic | Koriyama-shi | 963-8563 | Japan |
| Katayama Medical Clinic | Kurashiki-shi | 710-0813 | Japan |
| Mabashi Clinic | Matsudo-shi | 271-0047 | Japan |
| National Center for Geriatrics and Gerontology | Obu-shi | 474-8511 | Japan |
| Tokyo Medical University Hospital | Shinjuku-ku | 160-0023 | Japan |
| Tokyo Metropolitan Bokutoh Hospital | Sumida-ku | 130-8575 | Japan |
| Memory Clinic Toride | Toride-shi | 302-0004 | Japan |
| Yamagata University Hospital | Yamagata | 990-9585 | Japan |
| Oita University Hospital | Yufu-shi | 879-5593 | Japan |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000707472 | LY3154207 |
Not provided
Not provided
Not provided